A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Multi-Center Study to Evaluate the Effects of PT001 and PT005 on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD.
Phase of Trial: Phase III
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Formoterol (Primary) ; Glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 03 Jan 2017 Status changed from not yet recruiting to recruiting.
- 20 Oct 2016 New trial record